{"id":"h1-data-minimalism","assumption":"More comprehensive multi-modal datasets always improve drug repurposing predictions","hypothesis":"Strategically minimal, high-signal datasets can outperform large, noisy multi-modal approaches for rare diseases","impact":"Could unlock repurposing for ultra-rare conditions with extremely limited data","timestamp":"2025-08-13T05:08:00.000Z","status":"strongly-validated","literatureEvidence":"TxGNN (2024): DIRECT VALIDATION - Zero-shot learning for 17,000+ diseases without fine-tuning; K-Paths (2025): 90% data reduction with maintained performance; DrugCLIP (2024): Efficient learning without negative sampling; RareAgents (2024): Framework designed for data-limited rare diseases"}
{"id":"h2-actionability-first","assumption":"Predictive accuracy is the primary success metric for AI drug repurposing systems","hypothesis":"Models optimized for clinical actionability (interpretability, uncertainty quantification, decision support) outperform accuracy-optimized models","impact":"Could bridge the gap between AI predictions and clinical implementation","timestamp":"2025-08-13T05:08:00.000Z","status":"strongly-validated","literatureEvidence":"TxGNN (2024): DIRECT VALIDATION - Clinician-centered design with human-AI explorer validated by medical experts; RareAgents (2024): DIRECT VALIDATION - MDT coordination for clinical decision-making; DrugMCTS (2025): Structured reasoning for clinical decisions; DrugAgent (2024): Explainable results outperform black-box"}
{"id":"h3-cross-disease-patterns","assumption":"Each rare disease requires disease-specific computational models and approaches","hypothesis":"Shared mechanistic patterns across rare diseases can be leveraged through transfer learning and meta-learning approaches","impact":"Could enable repurposing for diseases with insufficient individual datasets","timestamp":"2025-08-13T05:08:00.000Z","status":"directly-validated","literatureEvidence":"TxGNN (2024): DIRECT VALIDATION - Single foundation model works across 17,080+ diseases with zero-shot transfer; DrugMCTS (2025): Multi-agent framework enables cross-disease pattern recognition"}
{"id":"h4-parallel-validation","assumption":"Drug validation must follow sequential preclinical â†’ clinical stages","hypothesis":"Parallel, multi-stage validation using real-world evidence can accelerate repurposing timelines without compromising safety","impact":"Could dramatically reduce time-to-treatment for rare disease patients","timestamp":"2025-08-13T05:08:00.000Z","status":"strongly-supported","literatureEvidence":"RareAgents (2024): DIRECT VALIDATION - MDT framework enables parallel assessment across specialties; DrugMCTS (2025): Parallel multi-agent evaluation across evidence types; TxGNN (2024): Simultaneous indication and contraindication prediction"}
{"id":"h5-human-ai-collaboration","assumption":"AI should minimize human bias and replace expert judgment in drug repurposing","hypothesis":"Hybrid human-AI systems that amplify rather than replace clinical expertise outperform fully automated approaches","impact":"Could leverage irreplaceable rare disease expertise while scaling discovery","timestamp":"2025-08-13T05:08:00.000Z","status":"comprehensively-validated","literatureEvidence":"TxGNN (2024): DIRECT VALIDATION - Expert-tested human-AI explorer interface validated by medical professionals; RareAgents (2024): DIRECT VALIDATION - Framework designed to augment clinical MDTs; Challa et al. (2021): DIRECT validation - human-AI collaboration outperforms either alone; DrugAgent (2024): Literature verification agent with interpretable reasoning"}